IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat is a research paper published in Journal of Neuro-Oncology (2021). On theSindex it has a DataRank of 0.669. It has been cited 18 times, with 14 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.442
From this paper's citation signal
Citation Network Contribution
0.228
From 12 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 14 citers.
National Institutes of Health
Grant: 5P50CA221747-02
SPORE for Translational Approaches to Brain Cancer
National Institutes of Health
Grant: 5R01NS118039-05
Targeting IDH mutations to improve seizure control in glioma patients
National Institutes of Health
Grant: 1R01NS117104-01
Interaction between Tissue Factor, Junctional Adhesion Molecule-A, and Integrin B1 to drive self-renewal in glioblastoma
National Institutes of Health
Grant: 5R01NS102669-02
Tissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and Malignancy
UC Davis Floyd and Mary Schwall Dissertation Fellowship
UC Davis Murray B. Gardner Junior Faculty Research Fellowship
Elsa U. Pardee Foundation
FWCI
0.81
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals